Literature DB >> 32566913

Molecular Pathogenesis and Interventional Strategies for Alzheimer's Disease: Promises and Pitfalls.

Shashikala Bhute1, Deepaneeta Sarmah1, Aishika Datta1, Pallavi Rane1, Amit Shard2, Avirag Goswami3, Anupom Borah4, Kiran Kalia1, Kunjan R Dave5, Pallab Bhattacharya1.   

Abstract

Alzheimer's disease (AD) is a debilitating disorder characterized by age-related dementia, which has no effective treatment to date. β-Amyloid depositions and hyperphosphorylated tau proteins are the main pathological hallmarks, along with oxidative stress, N-methyl-d-aspartate (NMDA) receptor-mediated excitotoxicity, and low levels of acetylcholine. Current pharmacotherapy for AD only provides symptomatic relief and limited improvement in cognitive functions. Many molecules have been explored that show promising outcomes in AD therapy and can regulate cellular survival through different pathways. To have a vivid approach to strategize the treatment regimen, AD physiopathology should be better explained considering diverse etiological factors in conjunction with biochemical disturbances. This Review attempts to discuss different disease modification approaches and address the novel therapeutic targets of AD that might pave the way for new drug discovery using the well-defined targets for therapy of the disease.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32566913      PMCID: PMC7296537          DOI: 10.1021/acsptsci.9b00104

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  189 in total

Review 1.  Neutrophils and macrophages work in concert as inducers and effectors of adaptive immunity against extracellular and intracellular microbial pathogens.

Authors:  Manuel T Silva
Journal:  J Leukoc Biol       Date:  2010-01-28       Impact factor: 4.962

2.  Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.

Authors:  Alireza Atri; Lutz Frölich; Clive Ballard; Pierre N Tariot; José Luis Molinuevo; Neli Boneva; Kristian Windfeld; Lars L Raket; Jeffrey L Cummings
Journal:  JAMA       Date:  2018-01-09       Impact factor: 56.272

3.  Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake.

Authors:  Takahisa Kanekiyo; Juan Zhang; Qiang Liu; Chia-Chen Liu; Lijuan Zhang; Guojun Bu
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

4.  Age-related differences in memory and executive functions in healthy APOE ɛ4 carriers: the contribution of individual differences in prefrontal volumes and systolic blood pressure.

Authors:  Andrew R Bender; Naftali Raz
Journal:  Neuropsychologia       Date:  2012-01-10       Impact factor: 3.139

Review 5.  On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis.

Authors:  Michael A Castello; Salvador Soriano
Journal:  Ageing Res Rev       Date:  2013-11-16       Impact factor: 10.895

6.  Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration.

Authors:  Qiang Liu; Justin Trotter; Juan Zhang; Melinda M Peters; Hua Cheng; Jianxin Bao; Xianlin Han; Edwin J Weeber; Guojun Bu
Journal:  J Neurosci       Date:  2010-12-15       Impact factor: 6.167

7.  The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease.

Authors:  A D Snow; H Mar; D Nochlin; K Kimata; M Kato; S Suzuki; J Hassell; T N Wight
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

Review 8.  MicroRNAs in Alzheimer's Disease: Diagnostic Markers or Therapeutic Agents?

Authors:  Francesco Angelucci; Katerina Cechova; Martin Valis; Kamil Kuca; Bing Zhang; Jakub Hort
Journal:  Front Pharmacol       Date:  2019-06-18       Impact factor: 5.810

9.  APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer's disease.

Authors:  J I Vélez; F Lopera; D Sepulveda-Falla; H R Patel; A S Johar; A Chuah; C Tobón; D Rivera; A Villegas; Y Cai; K Peng; R Arkell; F X Castellanos; S J Andrews; M F Silva Lara; P K Creagh; S Easteal; J de Leon; M L Wong; J Licinio; C A Mastronardi; M Arcos-Burgos
Journal:  Mol Psychiatry       Date:  2015-12-01       Impact factor: 15.992

Review 10.  Clinical trials of new drugs for Alzheimer disease.

Authors:  Li-Kai Huang; Shu-Ping Chao; Chaur-Jong Hu
Journal:  J Biomed Sci       Date:  2020-01-06       Impact factor: 8.410

View more
  3 in total

Review 1.  Apoptotic Pathways and Alzheimer's Disease: Probing Therapeutic Potential.

Authors:  Vivek Kumar Sharma; Thakur Gurjeet Singh; Shareen Singh; Nikhil Garg; Sonia Dhiman
Journal:  Neurochem Res       Date:  2021-08-12       Impact factor: 3.996

Review 2.  Regulation of mitochondrial dysfunction induced cell apoptosis is a potential therapeutic strategy for herbal medicine to treat neurodegenerative diseases.

Authors:  Ruo-Lan Li; Ling-Yu Wang; Hu-Xinyue Duan; Qing Zhang; Xiaohui Guo; Chunjie Wu; Wei Peng
Journal:  Front Pharmacol       Date:  2022-09-22       Impact factor: 5.988

Review 3.  microRNA-Based Biomarkers in Alzheimer's Disease (AD).

Authors:  Yuhai Zhao; Vivian Jaber; Peter N Alexandrov; Andrea Vergallo; Simone Lista; Harald Hampel; Walter J Lukiw
Journal:  Front Neurosci       Date:  2020-10-30       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.